- Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.)
-
Park D, Lee EK
- KMID: 2282016
- Endocrinol Metab.
- 2015 Jun;30(2):231-232.
- doi: 10.3803/EnM.2015.30.2.231
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
-
Lee S, Lee DY
- KMID: 2409795
- Ann Pediatr Endocrinol Metab.
- 2017 Mar;22(1):15-26.
- doi: 10.6065/apem.2017.22.1.15
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by... -
- CITED
-
- Close
- SHARE
-
- Close
- New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
-
Lee WY
- KMID: 2413278
- Endocrinol Metab.
- 2017 Mar;32(1):1-5.
- doi: 10.3803/EnM.2017.32.1.1
It is well known that both insulin resistance and decreased insulin secretory capacity are important factors in the pathogenesis of type 2 diabetes mellitus (T2DM). In addition to genetic factors,... -
- CITED
-
- Close
- SHARE
-
- Close
- Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.)
-
Jung MJ, Kwon SK
- KMID: 2282017
- Endocrinol Metab.
- 2015 Jun;30(2):233-234.
- doi: 10.3803/EnM.2015.30.2.233
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
-
Jung CH, Mok JO
- KMID: 2452623
- J Obes Metab Syndr.
- 2019 Mar;28(1):18-29.
- doi: 10.7570/jomes.2019.28.1.18
The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2)... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Kim HJ
- KMID: 2408656
- J Korean Diabetes.
- 2018 Mar;19(1):35-40.
- doi: 10.4093/jkd.2018.19.1.35
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
-
Min SH, Cho YM
- KMID: 2173851
- J Korean Diabetes.
- 2015 Dec;16(4):252-259.
- doi: 10.4093/jkd.2015.16.4.252
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including... -
- CITED
-
- Close
- SHARE
-
- Close
- Extrapancreatic Effect of Glucagon like Peptide-1
-
Jeong IK
- KMID: 2268972
- Korean J Med.
- 2015 Oct;89(4):404-412.
- doi: 10.3904/kjm.2015.89.4.404
Glucagon like peptide-1 (GLP-1) is an intestinal L cell derived incretin hormone which stimulates insulin secretion of beta cell and inhibits glucagon secretion of alpha cell of pancreatic islets. GLP-1... -
- CITED
-
- Close
- SHARE
-
- Close
- Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
-
Lee I, Kang ES
- KMID: 2458964
- J Korean Diabetes.
- 2019 Sep;20(3):149-156.
- doi: 10.4093/jkd.2019.20.3.149
According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
-
Kang YM, Jung CH
- KMID: 2308856
- Endocrinol Metab.
- 2016 Jun;31(2):258-274.
- doi: 10.3803/EnM.2016.31.2.258
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade.... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018
-
Kim JM, Kim SS
- KMID: 2442347
- J Korean Diabetes.
- 2019 Mar;20(1):6-9.
- doi: 10.4093/jkd.2019.20.1.6
In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the... -
- CITED
-
- Close
- SHARE
-
- Close
- New Therapeutics for Diabetes Using Incretin Hormone
-
Oh S
- KMID: 2259281
- Korean J Med.
- 2011 Jun;80(6):625-634.
New therapeutics for type 2 diabetes using incretin hormone were introduced recently. Incretin-based therapies consist of two types: GLP-1 agonists mainly acting on the GLP-1 receptor and dipeptidyl peptidase 4... -
- CITED
-
- Close
- SHARE
-
- Close
- Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018
-
Park JH
- KMID: 2415849
- J Korean Diabetes.
- 2018 Jun;19(2):71-75.
- doi: 10.4093/jkd.2018.19.2.71
The management of type 2 diabetes mellitus should comprise healthy lifestyle modifications along with tailored pharmacologic treatment. Traditionally, the American Diabetes Association (ADA)'s Diabetes Management Guidelines have not prioritized specific... -
- CITED
-
- Close
- SHARE
-
- Close
- Dipeptidyl Peptidase-4 Inhibitor
-
Lee DH
- KMID: 2269255
- Korean J Med.
- 2014 Jul;87(1):1-8.
Recent advances in incretin biology have led to the development of a new class of oral anti-diabetic drugs. To date, there are two known incretin hormones, glucagon-like peptide-1 (GLP-1) and... -
- CITED
-
- Close
- SHARE
-
- Close
- A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
-
Sargeant J, Henson J, King JA, Yates T, Khunti K, Davies MJ
- KMID: 2458626
- Endocrinol Metab.
- 2019 Sep;34(3):247-262.
- doi: 10.3803/EnM.2019.34.3.247
Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance
-
Jung MJ, Kwon SK
- KMID: 2384252
- Endocrinol Metab.
- 2014 Dec;29(4):536-544.
- doi: 10.3803/EnM.2014.29.4.536
BACKGROUND: Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes. Considering the large numbers of papillary thyroid carcinomas (PTCs) and possible effects of glucagon-like peptide-1... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Kim HJ, Park SO, Ko SH, Rhee SY, Hur KY, Kim NH, Moon MK, Lee BW, Kim JH, Choi KM, on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association
- KMID: 2398081
- Diabetes Metab J.
- 2017 Dec;41(6):423-429.
- doi: 10.4093/dmj.2017.41.6.423
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke
-
Kim S, Jeong J, Jung HS, Kim B, Kim YE, Lim DS, Kim SD, Song YS
- KMID: 2389009
- Exp Neurobiol.
- 2017 Aug;26(4):227-239.
- doi: 10.5607/en.2017.26.4.227
Glucagon like peptide-1 (GLP-1) stimulates glucose-dependent insulin secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which block inactivation of GLP-1, are currently in clinical use for type 2 diabetes mellitus. Recently, GLP-1 has... -
- CITED
-
- Close
- SHARE
-
- Close
- Genetic Polymorphism of Glucagon-Like Peptide 1 Receptor in Korean Type 2 Diabetes Mellitus
-
Lee KW, Jiang M, Piao S, Kim EA, Hong SB, Nam MS, Kim YS, Park KS, Lee HC
- KMID: 2177802
- J Korean Diabetes Assoc.
- 2005 Jan;29(1):30-38.
BACKGROUND: Glucagon-like peptide-1 (GLP-1) is a hormone secreted by intestinal L-cells, which stimulates insulin secretion from cells. The biological action of GLP-1 is mediated by the glucagon-like peptide-1... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
-
Oh S, Chon S, Ahn KJ, Jeong IK, Kim BJ, Kang JG
- KMID: 2281530
- Diabetes Metab J.
- 2015 Jun;39(3):177-187.
- doi: 10.4093/dmj.2015.39.3.177
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between... -
- CITED
-
- Close
- SHARE
-
- Close
